The United Kingdom and the United States have agreed to a landmark bilateral deal that will maintain no duties on British pharmaceutical shipments entering the US market.
Agreement Details of the Pact
Under the terms of the agreement, the UK has committed to boost funding on drugs through the NHS. This move guarantees that import taxes on these crucial products will be held at nothing for a duration of three years.
This development comes after recent warnings to significantly raise duties on patented drug imports, with increases mentioned as high as one hundred percent.
"This arrangement between the UK bolsters the worldwide climate for innovative medicines and introduces long-overdue fairness to American-British pharmaceutical trade," a release said.
Economic Impact
Medicines represent one of the UK's most significant goods shipped to the US, which is by far the largest destination for leading companies like GSK and AstraZeneca.
Statistics indicate that in the year prior to last September, the UK sold drugs valued at £11.1bn to the US. This amount made up 17.4% of British export trade in that period.
"This agreement safeguards work, stimulates investment and sets the stage for the UK to become a international leader for life sciences," the Business and Trade Secretary commented.
Detailed UK Commitments
The deal involves several specific commitments from the UK:
- Higher Cost Ceiling: The UK will increase the affordability limit at which it deems new medicines to be unaffordable by a quarter.
- Increased NHS Spending: There is a target to double total health service expenditure on treatments from 0.3% of Gross Domestic Product to 0.6 percent over the next decade.
- Refund Ceiling: The sum pharmaceutical firms must pay back to the NHS to prevent overspending will be limited at fifteen percent. Previously, rebates were more than twenty percent.
Industry Background
This agreement takes place against a ongoing tension between the sector and the British authorities over drug pricing and regulatory access.
The disagreement were heightened by claims that American patients were charged significantly more for the equivalent treatments than people in the other developed nations.
Over the last 18 months, several major pharmaceutical investments in the UK have been delayed or cancelled, while substantial expansions have been directed toward American operations.
The Science Minister publicly accepted that the NHS must increase expenditure on medicines, noting that its spending on drugs had declined as a share of its total funding over the past decade.
